세계의 신장암 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료 클래스별, 약리학 클래스별, 지역별, 경쟁별(2020-2030년)
Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class, By Pharmacologic Class, By Region & Competition, 2020-2030F
상품코드:1698085
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
신장암 치료제 세계 시장은 2024년 71억 5,000만 달러로 평가되었습니다. 예측 기간 동안 6.45%의 연평균 복합 성장률(CAGR)로 성장하여 2030년까지 강력한 성장을 보일 것으로 예상됩니다.
신장암은 신세포암으로도 알려져 있으며, 혈액 속 노폐물과 여분의 수분을 걸러 소변을 만드는 콩 모양의 기관인 신장에 발생하는 암의 일종입니다. 신장암은 의학적으로 신세포암(RCC)이라고 불리며, 효과적인 치료 전략이 필요한 복잡하고 어려운 질환입니다. 의학 연구의 발전과 의약품의 혁신이 가속화됨에 따라 몇 가지 주요 촉진요인이 신장암 치료제 시장의 성장과 진화를 촉진하고 있습니다. 표적치료제는 암세포의 성장과 생존에 필수적인 특정 분자나 경로를 억제하도록 설계된 약물의 한 유형입니다. 신장암의 경우, 표적치료제는 치료에 혁명을 일으켰습니다. 예를 들어, 수니티닙, 파조파닙, 악시티닙과 같은 티로신 키나아제 억제제(TKI)가 있습니다. 이 약제들은 종양의 성장과 혈관신생(새로운 혈관 형성)을 촉진하는 신호전달 경로를 파괴합니다. 이 약물의 도입으로 신장암 치료의 상황은 극적으로 변화했습니다. 과거에는 선택의 폭이 제한적이었던 환자들은 이제 생존율과 삶의 질을 향상시킬 수 있는 다양한 치료법을 이용할 수 있게 되었습니다. 연구가 진행됨에 따라 신장암 치료제 시장은 더 많은 진전을 이룰 것으로 보입니다. 병용요법, 개별화된 의료 접근법, 새로운 표적의 통합이 시야에 들어오고 있습니다. 또한 연구자, 제약회사, 의료 단체, 환자 지원 단체 간의 지속적인 협력 관계는 혁신적인 치료법 개발을 계속 형성하고 궁극적으로 신장암에 직면 한 환자의 결과를 개선하는 데 도움이 될 것입니다.
Global Kidney Cancer Drugs Market was valued at USD 7.15 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.45% through 2030. Kidney cancer, also known as renal cell carcinoma, is a type of cancer that originates in the kidneys, the bean-shaped organs responsible for filtering waste and excess fluids from the blood to form urine. Kidney cancer, medically termed renal cell carcinoma (RCC), is a complex and challenging disease that demands effective treatment strategies. As medical research advances and pharmaceutical innovation accelerates, several key drivers are propelling the growth and evolution of the kidney cancer drugs market. Targeted therapies are a class of drugs designed to inhibit specific molecules or pathways that are crucial for cancer cell growth and survival. In kidney cancer, targeted therapies have revolutionized treatment. Examples include tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and axitinib. These drugs disrupt the signaling pathways that promote tumor growth and angiogenesis (formation of new blood vessels). The landscape of kidney cancer treatment has been dramatically transformed by the introduction of these drugs. Patients who once faced limited options now have access to a range of therapies that offer improved survival rates and enhanced quality of life. As research continues, the kidney cancer drugs market is poised for further advancements. Combination therapies, personalized medicine approaches, and the integration of novel targets are on the horizon. Additionally, the ongoing collaboration among researchers, pharmaceutical companies, healthcare organizations, and patient advocacy groups will continue to shape the development of innovative therapies and ultimately lead to better outcomes for patients facing kidney cancer.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 7.15 Billion
Market Size 2030
USD 10.43 Billion
CAGR 2025-2030
6.45%
Fastest Growing Segment
Targeted Therapy
Largest Market
North America
Key Market Drivers
Rising Incidence of Kidney Cancer
The global kidney cancer market is experiencing significant expansion, largely driven by the rising incidence of kidney cancer worldwide. In 2022, kidney cancer accounted for 434,840 newly diagnosed cases globally, making it the 14th most prevalent cancer worldwide. It ranked as the 10th most diagnosed cancer among men and the 13th among women, underscoring its significant impact on global healthcare systems and oncology markets. The increasing number of renal cell carcinoma (RCC) cases-the most common type of kidney cancer-has created a growing demand for advanced diagnostics, innovative therapeutics, and improved healthcare infrastructure. This trend is not only shaping market dynamics but also influencing the strategic direction of pharmaceutical companies, healthcare providers, and investors. The global population is aging at an unprecedented rate. Between 1974 and 2024, the proportion of individuals aged 65 and older nearly doubled, rising from 5.5% to 10.3%, and age is a significant risk factor for kidney cancer. With higher life expectancy, the number of kidney cancer cases is expected to increase, driving demand for effective treatment options. Developed regions such as North America and Europe report higher incidence rates due to advanced screening programs and improved diagnostic capabilities. Meanwhile, emerging economies in Asia-Pacific are seeing rising cases due to lifestyle changes and increasing industrialization, leading to a higher demand for cancer therapeutics.
Key Market Challenges
Resistance and Treatment Heterogeneity
Despite the advancements in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Over time, tumors can evolve and adapt, rendering once-effective therapies ineffective. This challenge underscores the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Additionally, kidney cancer is not a homogeneous disease. Different subtypes and genetic variations contribute to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor that requires a deep understanding of tumor biology and personalized medicine approaches.
Key Market Trends
Personalized Medicine Revolution
The era of personalized medicine has dawned upon the field of kidney cancer treatment, offering immense promise for improved patient outcomes. With the advent of precision oncology, the one-size-fits-all approach to treatment is giving way to tailored interventions that account for individual genetic profiles and biomarker expression. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. Armed with this information, they can prescribe targeted therapies that are more likely to elicit a favorable response. This shift towards personalized treatment approaches not only enhances the efficacy of drugs but also minimizes the potential for adverse effects.
Key Market Players
Novartis AG
Pfizer Inc.
Bayer AG
Genentech Inc.
Bristol-Myers Squibb
Eisai Co., Ltd.
Exelixis Inc
Prometheus Laboratories Inc
Glaxosmithkline PLC.
F. Hoffmann-LA Roche AG
Report Scope:
In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Kidney Cancer Drugs Market, By Therapeutic Class:
Targeted Therapy
Immunotherapy
Chemotherapy
Kidney Cancer Drugs Market, By Pharmacologic Class:
Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
Cytokine Immunotherapy (IL-2)
Kidney Cancer Drugs Market, By Region:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.
Available Customizations:
Global Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Kidney Cancer Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
5.2.3. By Company (2024)
5.2.4. By Region
5.3. Market Map
6. North America Kidney Cancer Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutic Class
6.2.2. By Pharmacologic Class
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Kidney Cancer Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutic Class
6.3.1.2.2. By Pharmacologic Class
6.3.2. Mexico Kidney Cancer Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutic Class
6.3.2.2.2. By Pharmacologic Class
6.3.3. Canada Kidney Cancer Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutic Class
6.3.3.2.2. By Pharmacologic Class
7. Europe Kidney Cancer Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Therapeutic Class
7.2.2. By Pharmacologic Class
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Kidney Cancer Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutic Class
7.3.1.2.2. By Pharmacologic Class
7.3.2. Germany Kidney Cancer Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutic Class
7.3.2.2.2. By Pharmacologic Class
7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutic Class
7.3.3.2.2. By Pharmacologic Class
7.3.4. Italy Kidney Cancer Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutic Class
7.3.4.2.2. By Pharmacologic Class
7.3.5. Spain Kidney Cancer Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutic Class
7.3.5.2.2. By Pharmacologic Class
8. Asia-Pacific Kidney Cancer Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Therapeutic Class
8.2.2. By Pharmacologic Class
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Kidney Cancer Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutic Class
8.3.1.2.2. By Pharmacologic Class
8.3.2. India Kidney Cancer Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutic Class
8.3.2.2.2. By Pharmacologic Class
8.3.3. South Korea Kidney Cancer Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutic Class
8.3.3.2.2. By Pharmacologic Class
8.3.4. Japan Kidney Cancer Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutic Class
8.3.4.2.2. By Pharmacologic Class
8.3.5. Australia Kidney Cancer Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutic Class
8.3.5.2.2. By Pharmacologic Class
9. South America Kidney Cancer Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutic Class
9.2.2. By Pharmacologic Class
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Kidney Cancer Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutic Class
9.3.1.2.2. By Pharmacologic Class
9.3.2. Argentina Kidney Cancer Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutic Class
9.3.2.2.2. By Pharmacologic Class
9.3.3. Colombia Kidney Cancer Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutic Class
9.3.3.2.2. By Pharmacologic Class
10. Middle East and Africa Kidney Cancer Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutic Class
10.2.2. By Pharmacologic Class
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Kidney Cancer Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutic Class
10.3.1.2.2. By Pharmacologic Class
10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
